Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Darunavir (Prezista®) 800 mg once daily, co-administered with low dose ritonavir, is recommended as an option for use within NHS Wales for the treatment of HIV-1 infection in antiretroviral therapy experienced adults with no darunavir resistance associated mutations and who have plasma HIV-1 RNA <100,000 copies/mL and CD4+ cell count ≥100 cells x 10⁶/l. |
|||
|
|||
Medicine details |
|||
| Medicine name | darunavir (Prezista®) once daily | ||
| Formulation | once daily film-coated tablet | ||
| Reference number | 1336 | ||
| Indication | Co-administered with low dose ritonavir for the treatment of HIV-1 infection in antiretroviral therapy experienced adults with no darunavir resistance associated mutations and who have plasma HIV-1 RNA <100,000 copies/mL and CD4+ cell count ≥100 cells x 10⁶/l |
||
| Company | Janssen-Cilag Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 1812 | ||
| NMG meeting date | 12/06/2012 | ||
| AWMSG meeting date | 18/07/2012 | ||
| Ratification by Welsh Government | 07/08/2012 | ||
| Date of issue | 13/08/2012 | ||
| Date of last review | November 2022 | ||
| Further information This appraisal recommendation was reviewed in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations |
|||